WHO ICTRP trial
CROSS II.
NL-OMON20325 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON20325 |
|---|---|
| Public title | CROSS II. |
| Scientific title | Neoadjevant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinomas or squamous cell carcinomas of the esophagus. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Conditions | Esophageal cancer. |
| Interventions | Paclitaxel 50 mg/m2 and carboplatin AUC=2 on days 2, 8, 15, 22 and 29. Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Surgery (if randomised in this arm) will be preferably… |
| Registration date | Sep 16, 2005 |
| Target size | 350 |
| Secondary IDs | NL447;NTR487; : EMC 03-209 (CKTO 2004-13);ISRCTN80832026 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: